Pinealon

Not FDA approvedBioregulator ResearchBrain, mood & sleepLongevity & cellular
6.4

Worth trying, BioHarmony verdict

BioHarmony score 6.4 out of 10

Pinealon (Glu-Asp-Arg, or EDR) is a synthetic Khavinson tripeptide marketed for neuroprotection and cognition. Independent biophysics confirms it can contact DNA, per Silanteva 2019, but the only human data is a single uncontrolled cohort of 32, per Meshchaninov 2015, with no registered trial anywhere.

Read full report

What is Pinealon?

Pinealon is a synthetic tripeptide, Glu-Asp-Arg, usually shortened to EDR, and it is one of Vladimir Khavinson's short-peptide bioregulators developed in Russia. It gets marketed for neuroprotection, cognition, and brain aging. The short version of my read: the cell biology is genuinely interesting, but the human evidence simply is not there. There are no registered human trials anywhere, no FDA record, and no published effect size for human cognition. The strongest human data is a single open-label cohort of 32 people from the lab that created it, per Meshchaninov 2015, with no placebo and no blinding.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

Safety watch-outs

  • Any unexplained fatigue, easy bruising, or signs of low blood counts: stop and get a complete blood count, given the reported…
  • Any new neurological symptom while dosing an unproven grey-market peptide: stop and consult a clinician.
  • Injection-site reaction, fever, or signs of contamination from an injectable preparation: stop immediately, since sterility is unverified.
  • Any active or suspected cancer: do not use
  • a compound claimed to alter gene expression in cells has no safety data in that setting.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Pinealon yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingNo FDA-approved U.S. product is identified in the reviewed source set

Pinealon, also called the EDR tripeptide, has mechanistic, cell, animal, and limited Russian clinical literature. A 2020 review discusses possible gene-expression mechanisms, but the evidence does not establish an FDA-approved treatment.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.